FDA Mission Includes Clearer Efficacy Guidance – Vanderbilt’s Wood
This article was originally published in The Tan Sheet
Executive Summary
FDA's focus on post-marketing safety should be accompanied by clearer clinical efficacy standards, Vanderbilt Assistant Vice Chancellor Alastair Wood, MD, suggested during a March 6 hearing on user fees